Rapid assessment of coagulation activity in whole blood
First Claim
1. A method for measuring coagulation of blood, comprising obtaining blood from a mammal;
- inhibiting in vitro activation of the intrinsic contact activation pathway of coagulation in the blood;
initiating activation of the extrinsic activation pathway of coagulation by contacting the blood with at least one procoagulant; and
measuring coagulation of the blood.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention is directed to methods to rapidly assess the overall coagulant properties of a patient'"'"'s blood sample by inhibiting the activation of the intrinsic contact activation pathway of coagulation and activating the extrinsic pathway of coagulation. When the sample is whole blood, the resulting clotting time represents the overall coagulant activity of the plasma and cellular components of the blood, which is indicative of existing or impending pathology arising from abnormal coagulability. The invention also provides a method for measuring the risk of a patient for a thrombotic event and for monitoring the effectiveness of procoagulant/anticoagulant therapy. A blood collection apparatus suitable for use in for performing the methods of the invention is also provided.
139 Citations
50 Claims
-
1. A method for measuring coagulation of blood, comprising
obtaining blood from a mammal; -
inhibiting in vitro activation of the intrinsic contact activation pathway of coagulation in the blood;
initiating activation of the extrinsic activation pathway of coagulation by contacting the blood with at least one procoagulant; and
measuring coagulation of the blood. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 40)
-
-
33. A method for measuring the effectiveness of at least one coagulation factor or coagulation inhibitor on the coagulation of blood, comprising
obtaining blood from a mammal; -
dividing the blood into at least two aliquots;
treating the first aliquot to steps comprising;
(a) inhibiting in vitro activation of the intrinsic contact activation pathway of coagulation;
(b) initiating activation of the extrinsic activation pathway of coagulation by contacting the first aliquot with a procoagulant; and
(c) measuring coagulation of the first aliquot;
treating the second aliquot to steps comprising;
(d) inhibiting in vitro activation of the intrinsic contact activation pathway of coagulation in vitro;
(e) contacting the second aliquot with the at least one coagulation factor or coagulation inhibitor;
(f) initiating activation of the extrinsic activation pathway of coagulation by contacting the second aliquot with at least one procoagulant; and
(g) measuring coagulation of the second aliquot; and
(h) comparing coagulation measurements of the first and second aliquots. - View Dependent Claims (35, 36, 37, 38, 45, 46, 47)
-
-
34. A method for measuring the effectiveness of at least one coagulation factor or coagulation inhibitor on coagulation of a blood sample, comprising
obtaining a first blood sample from a mammal; -
inhibiting activation of the intrinsic contact activation pathway of coagulation;
initiating activation of the extrinsic activation pathway of coagulation by contacting the first blood sample with a procoagulant agent;
measuring coagulation of the first blood sample;
obtaining a second blood sample from the mammal;
inhibiting activation of the intrinsic contact activation pathway of coagulation;
contacting the second blood sample with at least one coagulation factor or inhibitor;
initiating activation of the extrinsic pathway of coagulation by contacting the second blood sample with at least one procoagulant;
measuring coagulation of the second blood sample; and
comparing coagulation measurements of the first and second blood samples. - View Dependent Claims (39, 48, 49, 50)
-
- 41. A blood collection apparatus comprising a vessel, wherein the vessel contains a contact activation pathway inhibitor.
-
44. A method for monitoring recovery of a patient from a condition related to abnormal blood coagulation, comprising:
-
obtaining at least two blood samples from a patient;
inhibiting activation of the intrinsic contact activation pathway of coagulation in the blood samples;
initiating activation of the extrinsic activation pathway of coagulation by contacting the blood samples with at least one procoagulant; and
measuring coagulation of the blood, wherein one of the blood samples is obtained before administration of medical treatment or a surgical procedure and the other blood samples are obtained during or after administration of the medical treatment or the surgical procedure.
-
Specification